• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Ivadradine.伊伐布雷定
Hosp Pharm. 2015 Oct;50(9):806-17. doi: 10.1310/hpj5009-806. Epub 2015 Oct 14.
2
Sacubitril/Valsartan.沙库巴曲缬沙坦
Hosp Pharm. 2015 Nov;50(11):1025-36. doi: 10.1310/hpj5011-1025. Epub 2015 Nov 24.
3
Cangrelor.坎格雷洛
Hosp Pharm. 2015 Nov;50(10):922-929. doi: 10.1310/hpj5010-922. Epub 2015 Nov 19.
4
Perampanel.吡仑帕奈
Hosp Pharm. 2013 Apr;48(4):321-31. doi: 10.1310/hpj4804-321.
5
Netupitant/Palonosetron.奈妥匹坦/帕洛诺司琼
Hosp Pharm. 2015 Apr;50(4):310-25. doi: 10.1310/hpj5004-310. Epub 2015 Apr 8.
6
Edoxaban.依度沙班
Hosp Pharm. 2015 Jul;50(7):619-34. doi: 10.1310/hpj5007-619. Epub 2015 Jul 31.
7
Secukinumab.司库奇尤单抗
Hosp Pharm. 2015 Sep;50(8):714-27. doi: 10.1310/hpj5008-714. Epub 2015 Sep 16.
8
Sofosbuvir.索磷布韦
Hosp Pharm. 2014 May;49(5):466-78. doi: 10.1310/hpj4905-466.
9
Linaclotide.利那洛肽
Hosp Pharm. 2013 Feb;48(2):143-52. doi: 10.1310/hpj4802-143.
10
Suvorexant.苏沃雷生
Hosp Pharm. 2015 Jan;50(1):59-71. doi: 10.1310/hpj5001-59.

本文引用的文献

1
Twenty-four-hour heart rate lowering with ivabradine in chronic heart failure: insights from the SHIFT Holter substudy.在慢性心力衰竭中使用伊伐布雷定实现 24 小时心率降低:SHIFT 动态心电图亚研究的见解。
Eur J Heart Fail. 2015 May;17(5):518-26. doi: 10.1002/ejhf.258. Epub 2015 Mar 20.
2
Effects of ivabradine therapy on heart failure biomarkers.伊伐布雷定治疗对心力衰竭生物标志物的影响。
Cardiol J. 2015;22(5):501-9. doi: 10.5603/CJ.a2015.0012. Epub 2015 Mar 3.
3
Ivabradine on aortic stiffness in patients with heart failure.伊伐布雷定对心力衰竭患者主动脉僵硬度的影响
J Investig Med. 2015 Apr;63(4):620-5. doi: 10.1097/JIM.0000000000000159.
4
Addition of ivabradine to β-blocker improves exercise capacity in systolic heart failure patients in a prospective, open-label study.在一项前瞻性、开放标签研究中,对于收缩性心力衰竭患者,在β受体阻滞剂基础上加用伊伐布雷定可改善运动能力。
Adv Ther. 2015 Feb;32(2):108-19. doi: 10.1007/s12325-015-0185-5. Epub 2015 Feb 21.
5
A case of atrial tachycardia treated with ivabradine as bridge to ablation.一例使用伊伐布雷定作为消融桥接治疗的房性心动过速病例。
J Cardiovasc Electrophysiol. 2015 May;26(5):565-8. doi: 10.1111/jce.12636. Epub 2015 Mar 18.
6
Nemaline myopathy and heart failure: role of ivabradine; a case report.棍状肌病与心力衰竭:伊伐布雷定的作用;病例报告
BMC Cardiovasc Disord. 2015 Jan 19;15:5. doi: 10.1186/1471-2261-15-5.
7
Ivabradine during cardiogenic shock: a clinical case and review of the literature.伊伐布雷定在心源性休克中的应用:1例临床病例及文献综述
Heart Lung. 2015 Jan-Feb;44(1):57-8. doi: 10.1016/j.hrtlng.2014.08.003. Epub 2014 Sep 18.
8
I(f) current inhibitor ivabradine in patients with idiopathic dilated cardiomyopathy: Impact on the exercise tolerance and quality of life.I(f) 伊伐布雷定对特发性扩张型心肌病患者的影响:对运动耐量和生活质量的影响 。 你提供的原文可能存在一些错误或不完整的地方,正确的可能是:Impact of the current inhibitor ivabradine in patients with idiopathic dilated cardiomyopathy: on the exercise tolerance and quality of life. 即“当前抑制剂伊伐布雷定对特发性扩张型心肌病患者的影响:对运动耐量和生活质量的影响” 。
Cardiol J. 2015;22(2):227-32. doi: 10.5603/CJ.a2014.0057. Epub 2014 Sep 2.
9
Ivabradine in stable coronary artery disease without clinical heart failure.稳定性冠状动脉疾病且无临床心力衰竭的伊伐布雷定。
N Engl J Med. 2014 Sep 18;371(12):1091-9. doi: 10.1056/NEJMoa1406430. Epub 2014 Aug 31.
10
Ivabradine treatment in a chronic heart failure patient cohort: symptom reduction and improvement in quality of life in clinical practice.慢性心力衰竭患者队列中的伊伐布雷定治疗:临床实践中症状减轻及生活质量改善
Adv Ther. 2014 Sep;31(9):961-74. doi: 10.1007/s12325-014-0147-3. Epub 2014 Aug 27.

伊伐布雷定

Ivadradine.

作者信息

Cada Dennis J, Bindler Ross, Baker Danial E

机构信息

Founder and Contributing Editor, The Formulary.

Drug Information Resident, College of Pharmacy, Washington State University Spokane.

出版信息

Hosp Pharm. 2015 Oct;50(9):806-17. doi: 10.1310/hpj5009-806. Epub 2015 Oct 14.

DOI:10.1310/hpj5009-806
PMID:26912922
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC4750831/
Abstract

Each month, subscribers to The Formulary Monograph Service receive 5 to 6 well-documented monographs on drugs that are newly released or are in late phase 3 trials. The monographs are targeted to Pharmacy & Therapeutics Committees. Subscribers also receive monthly 1-page summary monographs on agents that are useful for agendas and pharmacy/nursing in-services. A comprehensive target drug utilization evaluation/medication use evaluation (DUE/MUE) is also provided each month. With a subscription, the monographs are sent in print and are also available on-line. Monographs can be customized to meet the needs of a facility. A drug class review is now published monthly with The Formulary Monograph Service. Through the cooperation of The Formulary, Hospital Pharmacy publishes selected reviews in this column. For more information about The Formulary Monograph Service, call The Formulary at 800-322-4349. The October 2015 monograph topics are sacubitril/valsartan, daclatasvir, sonidegib, alirocumab, and sodium zirconium cyclosilicate. The Safety MUE is on sacubitril/valsartan.

摘要

每月,《处方集专论服务》的订阅者会收到5至6篇关于新发布或处于3期临床试验后期的药物的详细专论。这些专论面向药学与治疗学委员会。订阅者还会每月收到1页关于对议程以及药学/护理在职培训有用的药物的总结专论。每月还会提供一份全面的目标药物利用评估/用药使用评估(DUE/MUE)。订阅后,专论会以印刷形式发送,也可在线获取。专论可根据机构需求进行定制。现在每月会随《处方集专论服务》发布一份药物类别综述。通过《处方集》的合作,《医院药学》在本专栏发表精选综述。有关《处方集专论服务》的更多信息,请致电《处方集》800 - 322 - 4349。2015年10月的专论主题有沙库巴曲/缬沙坦、达卡他韦、索尼德吉、阿利西尤单抗和环硅锆酸钠。安全性MUE针对沙库巴曲/缬沙坦。